| Recruiting | Alendronate for Osteonecrosis in Adults With Sickle Cell Disease NCT06016634 | University of California, Davis | Phase 2 |
| Not Yet Recruiting | Awake Prone Positioning for Severe Acute Chest Syndrome NCT06698120 | Assistance Publique - Hôpitaux de Paris | N/A |
| Not Yet Recruiting | Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype NCT07282210 | Biossil Inc. | Phase 2 |
| Recruiting | Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Ch NCT07356050 | Children's Hospital Medical Center, Cincinnati | — |
| Active Not Recruiting | Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease NCT05675436 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Suspended | Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adul NCT05457790 | National Cancer Institute (NCI) | N/A |
| Recruiting | Pressure Pain Tolerance in Relation to Balance and Strength in Children NCT06529874 | Adly A Adam | N/A |
| Completed | Full Assessment of Clinical Transfusion Support NCT07094646 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Serial Assessment of Fertility Experiences NCT07116772 | Children's Hospital Medical Center, Cincinnati | — |
| Active Not Recruiting | Sickle Cell Disease (SCD) Bone Pain Study NCT05283148 | University of California, Davis | N/A |
| Completed | The Montreal Cognitive Assessment.Test in Adults With Sickle Cell Disease NCT05347043 | Assistance Publique - Hôpitaux de Paris | N/A |
| Recruiting | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thal NCT05477563 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Active Not Recruiting | Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Dis NCT05357482 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Terminated | A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Parti NCT06503458 | Sanguine Biosciences | — |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir NCT05169580 | Fulcrum Therapeutics | Phase 1 |
| Completed | Management of Severe Acute Malnutrition in SCD, in Northern Nigeria NCT03634488 | Vanderbilt University Medical Center | Phase 2 |
| Recruiting | A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD NCT04201210 | University of Regensburg | Phase 2 |
| Active Not Recruiting | Stroke Prevention in Young Adults With Sickle Cell Anemia NCT04808778 | Vanderbilt University Medical Center | — |
| Completed | Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease NCT04476277 | National Heart, Lung, and Blood Institute (NHLBI) | EARLY_Phase 1 |
| Enrolling By Invitation | A Long-term Follow-up Study in Participants Who Received CTX001 NCT04208529 | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Completed | Actigraphy Improvement With Voxelotor (ActIVe) Study NCT04400487 | Pfizer | Phase 4 |
| Completed | Voxelotor Sickle Cell Exercise Study NCT04581356 | Elizabeth Yang, MD, PhD | Phase 4 |
| Completed | ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19 NCT06831799 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Completed | The Afolabi Stroke Registry for Children and Young Adults With SCD in Northern Nigeria NCT04800809 | Vanderbilt University Medical Center | — |
| Completed | Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease NCT04255875 | Pfizer | Phase 1 |
| Unknown | Physical Rehabilitation in Sickle Cell Anemia NCT04705792 | Centro Universitário Augusto Motta | N/A |
| Recruiting | Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation NCT04093986 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With NCT04134299 | Axcella Health, Inc | N/A |
| Completed | Hydroxyurea Optimization Through Precision Study NCT03789591 | Lifespan | Phase 3 |
| Recruiting | T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias NCT03653338 | Paul Szabolcs | Phase 1 / Phase 2 |
| Completed | Shared-Decision Making for Hydroxyurea NCT03442114 | Children's Hospital Medical Center, Cincinnati | N/A |
| Completed | Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas NCT03128515 | Indiana University | Phase 3 |
| Completed | Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies NCT03020615 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With NCT02961218 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS) NCT02990598 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Fetal Hemoglobin Induction Treatment Metformin NCT02981329 | Baylor College of Medicine | EARLY_Phase 1 |
| Completed | Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan NCT02675790 | Vanderbilt University Medical Center | Phase 3 |
| Completed | The Influence of micro-and Macro Vascular Dysfunction on Clinical Severity in Adults With Sickle Cell Anemia ( NCT07277023 | Centre Hospitalier Universitaire de la Guadeloupe | N/A |
| Completed | SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia NCT02769845 | Children's Hospital Medical Center, Cincinnati | N/A |
| Unknown | Measures of Respiratory Health (MRH) NCT02657837 | The Hospital for Sick Children | — |
| Terminated | Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects NCT02433158 | GlycoMimetics Incorporated | Phase 3 |
| Completed | Hematopoietic Stem Cell Transplant for Sickle Cell Disease NCT02065596 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | The Role of Endothelin-1 in Sickle Cell Disease NCT02712346 | Augusta University | Phase 1 |
| Completed | Carbon Monoxide Measurement to Screen for Sickle Cell Disease NCT02530242 | UCSF Benioff Children's Hospital Oakland | N/A |
| Completed | Evaluation of the AMICUS RBCx System in Sickle Cell Patients NCT02372877 | Fenwal, Inc. | N/A |
| Completed | Decision Aid for Therapeutic Options In Sickle Cell Disease NCT02326597 | Emory University | N/A |
| Completed | Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea T NCT02149537 | Loyola University | Phase 4 |
| Terminated | Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease NCT02445144 | Albert Einstein College of Medicine | — |
| Withdrawn | Study of Beet Juice for Patients With Sickle Cell Anemia NCT02162225 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Novel Use Of Hydroxyurea in an African Region With Malaria NCT01976416 | Indiana University | Phase 3 |
| Completed | EXTEND EXpanding Treatment for Existing Neurological Disease NCT02556099 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Completed | Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia NCT02467257 | Al-Neelain University | Phase 1 / Phase 2 |
| Completed | Hepcidin Levels in Sickle Cell Disease (SCD) NCT02258997 | Kenneth Ataga, MD | — |
| Withdrawn | Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study NCT02090296 | Children's National Research Institute | Phase 2 |
| Completed | The Effect of Rivaroxaban in Sickle Cell Disease NCT02072668 | University of North Carolina, Chapel Hill | Phase 2 |
| Unknown | Neutrophil Extracellular Traps and Sickle Cell Disease NCT02004808 | Tel-Aviv Sourasky Medical Center | — |
| Withdrawn | Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis NCT01925001 | Sangart | Phase 2 |
| Completed | A Phase II Trial of Regadenoson in Sickle Cell Anemia NCT01788631 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644 | Sanguine Biosciences | — |
| Terminated | Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease NCT01894594 | University Hospitals Cleveland Medical Center | Phase 1 |
| Unknown | Effect of Exercise With and Without HMB on Body Composition and Muscle Strength in Sickle Cell Anaemia NCT04001907 | The University of The West Indies | N/A |
| Completed | Sickle Cell Disease - Stroke Prevention in Nigeria Trial NCT01801423 | Vanderbilt University Medical Center | N/A |
| Completed | A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease NCT01800526 | Bloodworks | Phase 1 / Phase 2 |
| Completed | Study of Ventilatory Mechanics in Patients With Sickle Cell Anemia NCT02565849 | Rio de Janeiro State University | — |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without He NCT01848691 | Ashutosh Lal | N/A |
| Completed | Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol NCT01783990 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Terminated | Effects of HQK-1001 in Patients With Sickle Cell Disease NCT01601340 | HemaQuest Pharmaceuticals Inc. | Phase 2 |
| Completed | Microvascular Blood Flow in Sickle Cell Anemia NCT01566890 | Versiti Blood Health | N/A |
| Terminated | Bi-Level Positive Airway Ventilation for Acute Chest Syndrome NCT01589926 | Albert Einstein College of Medicine | N/A |
| Terminated | Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) NCT01531387 | Children's Hospital Medical Center, Cincinnati | Phase 3 |
| Unknown | Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose NCT03114137 | Cardiologie et Développement | — |
| Completed | Losartan to Reverse Sickle Nephropathy NCT01479439 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Completed | Carbon Monoxide Levels and Sickle Cell Disease Severity NCT01547793 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Safety Study of MP4CO in Adult Sickle Cell Patients NCT01356485 | Sangart | Phase 1 |
| Unknown | Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study NCT01905787 | HaEmek Medical Center, Israel | — |
| Completed | The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia NCT01703104 | Lagos State University | Phase 1 / Phase 2 |
| Completed | Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia NCT01558076 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Completed | Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia NCT01506544 | Children's Mercy Hospital Kansas City | Phase 1 |
| Terminated | Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea NCT01425307 | Children's Hospital Medical Center, Cincinnati | Phase 3 |
| Completed | Sickle Cell Disease: A Retrospective Chart Review NCT01441375 | Novartis Pharmaceuticals | — |
| Completed | A Study of HQK-1001 in Patients With Sickle Cell Disease NCT01322269 | HemaQuest Pharmaceuticals Inc. | Phase 2 |
| Completed | Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders NCT01316796 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopat NCT01340404 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | State Of The Art Functional Imaging In Sickle Cell Disease NCT01137721 | St. Jude Children's Research Hospital | — |
| Completed | Prasugrel Versus Placebo in Adult Sickle Cell Disease NCT01167023 | Eli Lilly and Company | Phase 2 |
| Completed | A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia NCT01179217 | Emmaus Medical, Inc. | Phase 3 |
| Withdrawn | Ranibizumab for Neovascularization in Sickle Cell Retinopathy NCT00618644 | Kresge Eye Institute | N/A |
| Active Not Recruiting | Haploidentical PBMC Transplant for Severe Congenital Anemias NCT00977691 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 / Phase 2 |
| Completed | Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Sickle Cell Anemia NCT01783093 | Namita Sood | — |
| Completed | Effectiveness of New Analgesic Strategy Compared to the Usal Antalgic Strategy NCT00874172 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease NCT01000155 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil NCT00937144 | The Baruch Padeh Medical Center, Poriya | Phase 4 |
| Terminated | Treatment of Sickle Cell Anemia With Stem Cell Transplant NCT01350232 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | Exercise Capacity in Pediatric Sickle Cell Anemia NCT01527799 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Completed | Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects NCT00971880 | HaEmek Medical Center, Israel | — |
| Completed | The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia NCT00971698 | HaEmek Medical Center, Israel | — |
| Completed | Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia NCT00512564 | HaEmek Medical Center, Israel | — |
| Completed | Bone Marrow for Hemoglobinopathy Research NCT00669305 | St. Jude Children's Research Hospital | — |
| Completed | Clinical and Laboratory Characteristics of Sickle Cell Anemia Patients Admitted With Fever NCT00736060 | HaEmek Medical Center, Israel | — |
| Completed | Clinical Diagnosis of Teenagers Admitted to Pediatric Departments NCT00735540 | HaEmek Medical Center, Israel | — |
| Completed | Sickle Cell Anemia Screening and Prevention in Northern Israel NCT00735488 | HaEmek Medical Center, Israel | — |
| Completed | Adherence to Hydroxyurea in Children With Sickle Cell Anemia NCT00672789 | Duke University | N/A |
| Completed | Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia NCT00011648 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Recruiting | Blood Sampling for Research Related to Sickle Cell Disease NCT00542230 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Completed | Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia NCT00512226 | HaEmek Medical Center, Israel | N/A |
| Completed | Pulmonary Hypertension, Hypoxia and Sickle Cell Disease NCT00495638 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Completed | Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea NCT00480974 | HaEmek Medical Center, Israel | — |
| Withdrawn | Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia NCT00538564 | Johns Hopkins University | Phase 2 |
| Completed | Sickle Cell Disease and Endothelial Progenitor Cells (EPCs) NCT00783627 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain NCT00236093 | Cephalon | Phase 2 |
| Completed | Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemi NCT00399074 | Makerere University | Phase 3 |
| Completed | Exercise-induced Pulmonary Hypertension in Patients With Sickle-cell Anemia NCT00948012 | Federal University of São Paulo | — |
| Terminated | A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET NCT00360087 | Actelion | Phase 3 |
| Terminated | A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyur NCT00294541 | Icagen | Phase 3 |
| Completed | Invasive Infections in Children With Hemoglobinopathies NCT00456443 | HaEmek Medical Center, Israel | — |
| Completed | Heart Disease in Sickle Cell Anemia NCT00113152 | National Institutes of Health Clinical Center (CC) | — |
| Completed | Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial NCT00072761 | Washington University School of Medicine | Phase 3 |
| Completed | Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease NCT00095472 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia NCT00125788 | Emmaus Medical, Inc. | Phase 2 |
| Terminated | L-Glutamine Therapy for Sickle Cell Anemia NCT00586209 | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 2 |
| Completed | Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia NCT00056433 | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Completed | Hydroxyurea in Young Children With Sickle Cell Anemia NCT00519701 | Duke University | N/A |
| Completed | A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Ane NCT00040677 | Icagen | Phase 2 |
| Completed | Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension NCT00023296 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| Completed | Nitric Oxide to Improve Blood Flow in Sickle Cell Disease NCT00009581 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Terminated | Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies NCT00040469 | Baylor College of Medicine | Phase 2 |
| Terminated | Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies NCT00040417 | Baylor College of Medicine | Phase 2 |
| Completed | Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant He NCT00005893 | Fairview University Medical Center | N/A |
| Completed | A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disor NCT00005783 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 |
| Completed | Bone Marrow Transplantation in Treating Children With Sickle Cell Disease NCT00004485 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia NCT00004492 | University of North Carolina | Phase 1 / Phase 2 |
| Completed | Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syn NCT00004143 | David Rizzieri, MD | Phase 2 |
| Completed | Decompression Coring Versus Conservative Therapy in Patients With Avascular Necrosis of the Hip Related to Sic NCT00006130 | UCSF Benioff Children's Hospital Oakland | N/A |
| Completed | Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia NCT00001716 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease NCT00004408 | Mast Therapeutics, Inc. | Phase 3 |
| Completed | Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cel NCT00004412 | Susan P. Perrine | Phase 2 |
| Completed | Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes NCT00004404 | Boston Children's Hospital | N/A |
| Completed | Pilot Study of Fructose for Sickle Cell Crisis NCT00004797 | National Center for Research Resources (NCRR) | N/A |
| Completed | Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis NCT00578435 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia NCT00001197 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Unknown | Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thal NCT01092169 | Hillel Yaffe Medical Center | — |